首页> 外国专利> Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of Dengue virus infection

Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of Dengue virus infection

机译:预防,治疗和诊断登革热病毒感染的细胞毒性T淋巴细胞免疫原

摘要

Dengue Fever (DF) and Dengue Hemorrhagic Fever (DHR) are significant global public health problems and understanding the overall immune response to infection will contribute to appropriate management of the disease and its potentially severe complications. Live attenuated and subunit vaccine candidates, which are under clinical evaluation, induce primarily an antibody response to the virus and minimal cross-reactive T cell responses. Currently, there are no available tools to assess protective T cell responses during infection or post vaccination. The disclosure incorporates immunoproteomics to uncover novel HLA-A2 specific epitopes derived from Dengue Virus (DV)- infected cells. These epitopes are conserved with epitope-specific CTLs cross-reacting against all four DV serotypes. These epitopes have potential as new informational and diagnostic tools to characterize T cell immunity in Dengue virus (DV) infection, and serves as a universal vaccine candidate complementary to current vaccines.
机译:登革热(DF)和登革热出血热(DHR)是重大的全球公共卫生问题,了解对感染的总体免疫反应将有助于对该疾病及其潜在严重并发症的适当管理。正在临床评估中的减毒活疫苗和亚单位疫苗候选物主要诱导针对病毒的抗体反应和最小的交叉反应性T细胞反应。当前,没有可用的工具来评估感染或疫苗接种后的保护性T细胞反应。本公开内容掺入了免疫蛋白质组学以发现衍生自登革热病毒(DV)感染的细胞的新颖的HLA-A2特异性表位。这些表位与针对所有四种DV血清型交叉反应的表位特异性CTL保守。这些表位作为登革热病毒(DV)感染中T细胞免疫特征的新信息和诊断工具具有潜力,并可以作为通用疫苗的补充,作为当前疫苗的补充。

著录项

  • 公开/公告号AU2012275319A1

    专利类型

  • 公开/公告日2013-11-14

    原文格式PDF

  • 申请/专利权人 IMMUNOTOPE INC.;

    申请/专利号AU2012275319A1

  • 发明设计人 PHILIP RAMILA;

    申请日2012-06-28

  • 分类号A61K39/12;A61K38;A61K38/08;

  • 国家 AU

  • 入库时间 2022-08-21 15:53:08

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号